MUC1 and neoplasm: Therefore, mimicry of the Gal-epitope by MUC1 might skew Th2 type responses to MUC1 vaccines, which is contradictory to the present paradigm that stresses Th1 responses as being beneficial to MUC1 and other tumor-associated antigens.